Citations

Clear

3042 citation(s) found for "Kumar, S".

Intra-articular Lipoma of the Pisotriquetral Joint: A Rare Case Report
Mettu, Sindhura, Gavvala, Sai Niharika, Shirodkar, Kapil , Iyengar, Karthikeyan P. , Papineni, Vijay Ram Kumar , Iyengar, Karthikeyan Parthasarathy , Botchu, Rajesh

Mayo Clinic

Indian Journal of Radiology and Imaging | February 24, 2024 | Volume: 34 | Issue: 03 | Pages: 558-561

10.1055/s-0044-1779521 | PMID 38912239 Get It

AbstractIntra-articular lipomas are infrequently reported, with most reported cases occurring in the knee joint. A case of intra-articular lipoma in the small joints of the hand, specifically in the pisotriquetral joint, has been documented for the first time. A 24-year-old male visited the emergency department after a road traffic accident with a painful and swollen wrist. Radiographic examination revealed fractures of the distal radius and triquetrum. A subsequent wrist computed tomography scan identified an intra-articular lipoma within the pisotriquetral joint, further confirmed by ultrasonography. This article underscores the importance of recognizing that, though exceedingly rare, intra-articular lipomas should be considered in the differential diagnosis of soft-tissue tumors affecting the hand and wrist.
Impact of Deltoid Computer Tomography Image Data on the Accuracy of Machine Learning Predictions of Clinical Outcomes after Anatomic and Reverse Total Shoulder Arthroplasty
Rajabzadeh-Oghaz, Hamidreza , Berry, David B. , Singh, Anshu , Aibinder, William R. , Gobbato, Bruno , Polakovic, Sandrine , Elwell, Josie , Roche, Christopher , Berry, David B , Roche, Christopher P , Aibinder, William R , Kumar, Vikas , Schoch, Bradley S.

Mayo Clinic

Journal of Clinical Medicine | February 23, 2024 | Volume: 13 | Issue: 5 | Pages: 1273

10.3390/jcm13051273 | PMID 38592118 Get It

Background: Despite the importance of the deltoid to shoulder biomechanics, very few studies have quantified the three-dimensional shape, size, or quality of the deltoid muscle, and no studies have correlated these measurements to clinical outcomes after anatomic (aTSA) and/or reverse (rTSA) total shoulder arthroplasty in any statistically/scientifically relevant manner. Methods: Preoperative computer tomography (CT) images from 1057 patients (585 female, 469 male; 799 primary rTSA and 258 primary aTSA) of a single platform shoulder arthroplasty prosthesis (Equinoxe; Exactech, Inc., Gainesville, FL) were analyzed in this study. A machine learning (ML) framework was used to segment the deltoid muscle for 1057 patients and quantify 15 different muscle characteristics, including volumetric (size, shape, etc.) and intensity-based Hounsfield (HU) measurements. These deltoid measurements were correlated to postoperative clinical outcomes and utilized as inputs to train/test ML algorithms used to predict postoperative outcomes at multiple postoperative timepoints (1 year, 2–3 years, and 3–5 years) for aTSA and rTSA. Results: Numerous deltoid muscle measurements were demonstrated to significantly vary with age, gender, prosthesis type, and CT image kernel; notably, normalized deltoid volume and deltoid fatty infiltration were demonstrated to be relevant to preoperative and postoperative clinical outcomes after aTSA and rTSA. Incorporating deltoid image data into the ML models improved clinical outcome prediction accuracy relative to ML algorithms without image data, particularly for the prediction of abduction and forward elevation after aTSA and rTSA. Analyzing ML feature importance facilitated rank-ordering of the deltoid image measurements relevant to aTSA and rTSA clinical outcomes. Specifically, we identified that deltoid shape flatness, normalized deltoid volume, deltoid voxel skewness, and deltoid shape sphericity were the most predictive image-based features used to predict clinical outcomes after aTSA and rTSA. Many of these deltoid measurements were found to be more predictive of aTSA and rTSA postoperative outcomes than patient demographic data, comorbidity data, and diagnosis data. Conclusions: While future work is required to further refine the ML models, which include additional shoulder muscles, like the rotator cuff, our results show promise that the developed ML framework can be used to evolve traditional CT-based preoperative planning software into an evidence-based ML clinical decision support tool.
Extended Long-Term Outcomes of Single-Fraction Stereotactic Radiosurgery for Primary Management of Sporadic Meningiomas
Graffeo, Christopher S. , Brown, Paul D. , Link, Michael J. , Pollock, Bruce E. , Carlstrom, Lucas P. , Kumar, Rahul

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1779961 Get It

Application of tele-neuropsychology and tele-mental health before and during COVID-19 era: a bibliometric analysis
Ali, Abraish , Zafar, Rameen , Shariq, Kainat, Motiani, Vanita, Farhat, H. , Kumar, Kanwal Ashok , Ibrahim, Sufyan

Mayo Clinic

Annals of Medicine & Surgery | February 17, 2024 | Volume: 86 | Issue: 5 | Pages: 2777-2785

10.1097/ms9.0000000000001822 | PMID 38694297 Get It

Background: Telehealth use was previously limited by strict regulations and financial constraints. However, the pandemic prompted some countries to ease their telehealth laws. Thus, we conducted a bibliometric analysis and network visualization to gauge changes in tele-neuropsychology (Tele-NP) and tele-mental Health (Tele-MH) trends with the onset of the COVID-19 pandemic. Materials and methods: The authors conducted a literature search on SCOPUS and included relevant articles pertaining to Tele-NP and Tele-MH, which were published before the COVID-19 pandemic (2017–2019) and during the COVID-19 pandemic (2020–2022). The authors presented publication patterns on psychiatric disorders, mode of administration, journals, active countries, authors, affiliations, funding sponsors, keywords, publication, and citation output. Results: Three hundred forty-one articles were included in our study with 80 articles before the pandemic and 261 during the pandemic. Our analysis revealed the greatest increase in publications and citations output was from the year 2020 to 2021. A greater number of journals published tele-NP and tele-MH-related research, with higher frequency, during the COVID-19 pandemic with Telemedicine and E-health leading the way. WHO regional analysis revealed that the Region of the Americas (AMRO) was the leading contributor in terms of publications. Harvard Medical Center remained the number one contributor both before and during the COVID-19- pandemic. Publications by funding sponsors, particularly by those that were US-based, increased twice as much during the pandemic. Conclusion: The increase in research output following the COVID-19 outbreak reflects the growing interest and relevance of telemedicine for the delivery of mental health services.
The relevance of biologically effective dose for pain relief and sensory dysfunction after Gamma Knife radiosurgery for trigeminal neuralgia: an 871-patient multicenter study
Warnick, Ronald E. , Adam, Elizabeth , Iorio‐Morin, Christian , Leduc, William, Hamel, Andréanne, Johnson, Sarah E. , Bydon, Mohamad , Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Waite, Kaitlin, Jose, Shalini, Peker, Selçuk , Samanci, Mustafa Yavuz, Tek, Ece, Pikis, Stylianos , Sheehan, Jason P. , Kumar, Narendra , Bernstein, Kenneth , Ahorukomeye, Peter , Kshettry, Varun R. , Hernández, Wenceslao, Urgošík, Dušan, Lee, John Y. K., Patel, Samir , Kusyk, Dorian , Shepard, Matthew J., Samancı, Yavuz , Paddick, Ian , Mathieu, David , Mantziaris, Georgios , Tripathi, Manjul , Alzate, Juan Diego , Speckter, Herwin , Liščák, Roman , Yang, Andrew I. , Kondziolka, Douglas

Mayo Clinic

Journal of Neurosurgery | February 17, 2024 | Volume: 141 | Issue: 2 | Pages: 461-473

10.3171/2023.12.jns231569 | PMID 38364220 Get It

OBJECTIVE Recent studies have suggested that biologically effective dose (BED) is an important correlate of pain relief and sensory dysfunction after Gamma Knife radiosurgery (GKRS) for trigeminal neuralgia (TN). The goal of this study was to determine if BED is superior to prescription dose in predicting outcomes in TN patients undergoing GKRS as a first procedure. METHODS This was a retrospective study of 871 patients with type 1 TN from 13 GKRS centers. Patient demographics, pain characteristics, treatment parameters, and outcomes were reviewed. BED was compared with prescription dose and other dosimetric factors for their predictive value. RESULTS The median age of the patients was 68 years, and 60% were female. Nearly 70% of patients experienced pain in the V2 and/or V3 dermatomes, predominantly on the right side (60%). Most patients had modified BNI Pain Intensity Scale grade IV or V pain (89.2%) and were taking 1 or 2 pain medications (74.1%). The median prescription dose was 80 Gy (range 62.5–95 Gy). The proximal trigeminal nerve was targeted in 77.9% of cases, and the median follow-up was 21 months (range 6–156 months). Initial pain relief (modified BNI Pain Intensity Scale grades I–IIIa) was noted in 81.8% of evaluable patients at a median of 30 days. Of 709 patients who achieved initial pain relief, 42.3% experienced at least one pain recurrence after GKRS at a median of 44 months, with 49.0% of these patients undergoing a second procedure. New-onset facial numbness occurred in 25.3% of patients after a median of 8 months. Age ≥ 63 years was associated with a higher probability of both initial pain relief and maintaining pain relief. A distal target location was associated with a higher probability of initial and long-term pain relief, but also a higher incidence of sensory dysfunction. BED ≥ 2100 Gy2.47 was predictive of pain relief at 30 days and 1 year for the distal target, whereas physical dose ≥ 85 Gy was significant for the proximal target, but the restricted range of BED values in this subgroup could be a confounding factor. A maximum brainstem point dose ≥ 29.5 Gy was associated with a higher probability of bothersome facial numbness. CONCLUSIONS BED and physical dose were both predictive of pain relief and could be used as treatment planning goals for distal and proximal targets, respectively, while considering maximum brainstem point dose < 29.5 Gy as a potential constraint for bothersome numbness.
Don’t let the genie out of the bottle!
Kumar, Shaji

Mayo Clinic

Blood | February 15, 2024 | Volume: 143 | Issue: 7 | Pages: 564-566

10.1182/blood.2023023293 | PMID 38358852 Get It

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma
Szlosarek, Peter W. , Creelan, Ben , Sarkodie, Thomas, Nolan, Luke, Olevsky, Olga, Grosso, Federica , Roy, Amy, Gilligan, David , Kindler, Hedy L. , Papadatos-Pastos, Dionysis, O’Byrne, Kenneth J. , Nowak, Anna K. , Steele, Jeremy, Sheaff, Michael , Shiu, Chiung‐Fang, Kuo, Chih‐Ling, Johnston, Amanda , Group, ATOMIC-Meso Study, Mackean, Melanie , Steele, Nicola , Upadhyay, Sunil , Srivastav, Ratnesh Kumar , Mencoboni, Manlio, Zilembo, Nicoletta, Marinis, Filippo de , Stella, Maria Giulia, Wang, Chin‐Chou , Nowak, Anna K , Taylor, Paul D. , Cortinovis, Diego Luigi , Chitnis, Meenali M. , Ceresoli, Giovanni Luca , Mansfield, Aaron S. , Tsao, Anne S. , Bomalaski, John S. , Zauderer, Marjorie G. , Fennell, Dean Anthony , Group, ATOMIC-Meso Study, Rybkin, Igor I. , Rolfo, Christian , Franks, K. , Shaw, Paul Nicholas , Lind, Michael , John, Thomas , Karapetis, Christos Stelios , Chella, Antonio , Stella, Maria Giulia, Chong, Inn‐Wen

Mayo Clinic

JAMA Oncology | February 15, 2024 | Volume: 10 | Issue: 4 | Pages: 475

10.1001/jamaoncol.2023.6789 | PMID 38358753 Get It

ImportanceArginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in patients with nonepithelioid pleural mesothelioma.ObjectiveTo determine the effect of pegargiminase-based chemotherapy on survival in nonepithelioid pleural mesothelioma, an arginine-auxotrophic tumor.Design, Setting, and ParticipantsThis was a phase 2-3, double-blind randomized clinical trial conducted at 43 centers in 5 countries that included patients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15, 2021, with at least 12 months’ follow-up. Final follow-up was on August 15, 2022. Data analysis was performed from March 2018 to June 2023.InterventionPatients were randomly assigned (1:1) to receive weekly intramuscular pegargiminase (36.8 mg/m2) or placebo. All patients received intravenous pemetrexed (500 mg/m2) and platinum (75-mg/m2 cisplatin or carboplatin area under the curve 5) chemotherapy every 3 weeks up to 6 cycles. Pegargiminase or placebo was continued until progression, toxicity, or 24 months.Main Outcomes and MeasuresThe primary end point was overall survival, and secondary end points were progression-free survival and safety. Response rate by blinded independent central review was assessed in the phase 2 portion only.ResultsAmong 249 randomized patients (mean [SD] age, 69.5 [7.9] years; 43 female individuals [17.3%] and 206 male individuals [82.7%]), all were included in the analysis. The median overall survival was 9.3 months (95% CI, 7.9-11.8 months) with pegargiminase-chemotherapy as compared with 7.7 months (95% CI, 6.1-9.5 months) with placebo-chemotherapy (hazard ratio [HR] for death, 0.71; 95% CI, 0.55-0.93; P = .02). The median progression-free survival was 6.2 months (95% CI, 5.8-7.4 months) with pegargiminase-chemotherapy as compared with 5.6 months (95% CI, 4.1-5.9 months) with placebo-chemotherapy (HR, 0.65; 95% CI, 0.46-0.90; P = .02). Grade 3 to 4 adverse events with pegargiminase occurred in 36 patients (28.8%) and with placebo in 21 patients (16.9%); drug hypersensitivity and skin reactions occurred in the experimental arm in 3 patients (2.4%) and 2 patients (1.6%), respectively, and none in the placebo arm. Rates of poststudy treatments were comparable in both arms (57 patients [45.6%] with pegargiminase vs 58 patients [46.8%] with placebo).Conclusions and RelevanceIn this randomized clinical trial of arginine depletion with pegargiminase plus chemotherapy, survival was extended beyond standard chemotherapy with a favorable safety profile in patients with nonepithelioid pleural mesothelioma. Pegargiminase-based chemotherapy as a novel antimetabolite strategy for mesothelioma validates wider clinical testing in oncology.Trial RegistrationClinicalTrials.gov Identifier: NCT02709512
Multimodality Imaging in Metabolic Syndrome: State-of-the-Art Review
Kalisz, Kevin , Navin, Patrick J. , Agarwal, Amit , Venkatesh, Sudhakar K. , Itani, Malak , Agarwal, Amit Kumar , Venkatesh, Sudhakar K , Rajiah, Prabhakar , Navin, Patrick , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | February 8, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1148/rg.230083 | PMID 38329901 Get It

Metabolomic biomarkers for (R, S)‐ketamine and (S)‐ketamine in treatment‐resistant depression and healthy controls: A systematic review
Kumar, Rakesh , Núñez, Nicolás A. , Joshi, Neha , Verde, Alessandra , Seshadri, Ashok , Singh, Balwinder , Joseph, Boney , Verde, Alessandra , Singh, Balwinder , Kumar, Rakesh , Joshi, Neha S , Joseph, Boney , Cuéllar‐Barboza, Alfredo B. , Prokop, Larry J. , Medeiros, Gustavo C.

Mayo Clinic

Bipolar Disorders | February 8, 2024 | Volume: 26 | Issue: 4 | Pages: 321-330

10.1111/bdi.13412 | PMID 38326104 Get It

AbstractBackgroundKetamine is increasingly used for treatment‐resistant depression (TRD) while its mechanism of action is still being investigated. In this systematic review, we appraise the current evidence of metabolomic biomarkers for racemic ketamine and esketamine in patients with TRD and healthy controls (HCs).MethodsA comprehensive search of several databases (Ovid MEDLINE®, Embase, and Epub Ahead of Print) was performed from each database's inception to June 29, 2022, in any language, was conducted. We included studies wherein the metabolomic biomarkers for racemic ketamine or esketamine were investigated in TRD or HCs. Our main outcomes were to examine changes in metabolites among patients treated with ketamine/esketamine and explore the association with response to ketamine/esketamine.ResultsA total of 1859 abstracts were screened of which 11 were included for full‐text review. Of these, a total of five articles were included (N = 147), including three RCTs (n = 129) and two open‐label trials (n = 18). All studies used racemic ketamine; one study additionally used esketamine. The included studies evaluated patients with treatment‐resistant bipolar depression (n = 22), unipolar depression (n = 91), and HCs (n = 34). The included studies reported alteration in several metabolites including acylcarnitines, lipids, kynurenine (KYN), and arginine with ketamine in TRD. Studies suggest the involvement of energy metabolism, KYN, and arginine pathways. In HCs, acetylcarnitine decreased post‐infusion, whereas inconsistent findings were observed after the ketamine infusion in TRD patients.ConclusionsThis systematic review provides preliminary evidence that ketamine may cause changes in several important pathways involved in energy metabolism and inflammation. Larger and more rigorous studies are needed.